Suppr超能文献

俄罗斯获得性别确认激素疗法的情况:跨性别者和内分泌学家的观点。

Access to gender-affirming hormonal therapy in Russia: perspectives of trans people and endocrinologists.

作者信息

Kirey-Sitnikova Yana

机构信息

BMC Chemistry, Uppsala University, Uppsala, Sweden.

出版信息

Int J Transgend Health. 2023 Oct 23;25(4):778-790. doi: 10.1080/26895269.2023.2272145. eCollection 2024.

Abstract

PURPOSE

Worldwide, trans people are known to take hormones without prescription or take higher or lower doses than prescribed. The study's goal was examination of the social context behind provision and receiving of gender-affirming hormonal therapy (GAHT) in Russia, as well as collection of opinions on the organization of healthcare.

METHODS

Semi-structured interviews with 20 trans individuals and 6 endocrinologists.

RESULTS

Trans respondents started GAHT between 2004 and 2022. Over that period, the number of trans-competent endocrinologists increased and it became easier to receive the diagnosis F64.0 "transsexualism" (ICD-10), which qualifies one to obtain GAHT. However, the majority still took hormones without supervision. The reasons for self-medication included: the lack of the diagnosis, high cost of appointments and tests, age under 18, and self-perceived understanding of principles of GAHT. Most endocrinologists learnt about GAHT after being approached by a trans patient. They received information from advanced training courses and academic literature. The specialists had diverse opinions on the ideal policy of providing GAHT to trans people, but all claimed that in Russian political realities they found the diagnosis "transsexualism" a necessary prerequisite for initiating GAHT to safeguard both doctors and patients.

CONCLUSIONS

The lack of strict law enforcement in the pharmacological sphere in Russia enabled many trans people to initiate GAHT without supervision. Trans-competent endocrinologists were available for those who needed them. Under current political circumstances it is unlikely that the informed consent model (prescription without a psychiatric diagnosis) can be implemented in Russia.

摘要

目的

在全球范围内,已知跨性别者会在没有处方的情况下服用激素,或者服用高于或低于规定剂量的激素。该研究的目标是考察俄罗斯提供和接受性别肯定激素疗法(GAHT)背后的社会背景,以及收集关于医疗保健组织的意见。

方法

对20名跨性别者和6名内分泌学家进行半结构化访谈。

结果

跨性别受访者在2004年至2022年期间开始接受GAHT。在此期间,具备跨性别专业知识的内分泌学家数量增加,获得“变性欲”(国际疾病分类第十版,F64.0)这一诊断变得更容易,而该诊断使患者有资格获得GAHT。然而,大多数人仍在无监督的情况下服用激素。自我用药的原因包括:缺乏诊断、预约和检查费用高昂、年龄不满18岁以及自我感觉对GAHT原则的理解。大多数内分泌学家是在有跨性别患者找他们之后才了解到GAHT的。他们从进阶培训课程和学术文献中获取信息。专家们对于为跨性别者提供GAHT的理想政策有不同意见,但都声称在俄罗斯的政治现实中,他们发现“变性欲”诊断是启动GAHT以保护医生和患者的必要前提。

结论

俄罗斯在药理学领域缺乏严格执法,使得许多跨性别者能够在无监督的情况下启动GAHT。有跨性别专业知识的内分泌学家可供有需要的人使用。在当前政治环境下,俄罗斯不太可能实施知情同意模式(无精神科诊断的处方)。

相似文献

本文引用的文献

1
Standards of Care for the Health of Transgender and Gender Diverse People, Version 8.《跨性别和性别多样化人群健康照护标准》第8版
Int J Transgend Health. 2022 Sep 6;23(Suppl 1):S1-S259. doi: 10.1080/26895269.2022.2100644. eCollection 2022.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验